37 results
Thumbnail

D2.505 - Sustainable Allergy Management: a Task force report

Thumbnail

D2.507 - School dust Streptomyces and Mycobacterium exposure and respiratory health in European children: the SINPHONIE study

Thumbnail

D2.516 - Can social media track seasonal allergy burden? An evidence-weighted geo-location pipeline and validation against airborne pollen exposure in Augsburg, Germany

Thumbnail

D2.506 - Mold amounts decreased annual concentration, even some species faded away with allergic sensitization rate in Seoul for 28 years

Thumbnail

D2.508 - Climate Change, Allergic Diseases, and Mental Health in Outdoor Workers: A Transdisciplinary Perspective from CliMent COST Action

Thumbnail

D2.509 - Do macrophages modulate the response of injured bronchial epithelium after PM2.5 and microplastic exposure?

Thumbnail

D2.511 - Beyond PFAS: Atypical oral manifestation of eosinophilic esophagitis in a patient with birch allergy. Case Description

Thumbnail

D2.512 - Analysis of temporal and regional trends in Internet searches for pollen allergies (MELIUS)

Thumbnail

D2.513 - Weed pollen exposure in Almaty: aerobiological monitoring and component-resolved IgE sensitization patterns

Thumbnail

D2.514 - Breathing zone pollen and fungal spore monitoring with an IOM Personal Sampler: A pilot study

Thumbnail

D2.515 - Symptom forecasting for birch and grass pollen allergy: the #berlinbreathing project

Thumbnail

D2.517 - #berlinbreathing : An app-based citizen science project for pollen allergies

Thumbnail

D2.518 - Clinical pattern of weed pollen sensitization in a Romanian population

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria